Comprehensive Microbiome-based AI Discovery Solutions – guided by a seasoned board and executive team, BluMaiden Biosciences delivers value-added outcomes to Pharma and Industry participants within clinical trials and drug discovery endavors.
BluMaiden Biosciences’ scientific team operates in Singapore and Europe, supported by the founding team based in Singapore. Our worldwide network thrives through science advisors, partners, and investors, consistently expanding to drive expertise.
Inclusive teams enhance our product, services, and partnerships, benefiting stakeholders from diverse backgrounds. We continually learn and adapt through central and team-based initiatives – locally, regionally, and globally. While aware of our current team’s composition gap, BluMaiden Biosciences is proactively recruiting diverse candidates to achieve our goals. As an early-stage company, rapid business plan advancement is crucial, driven by expertise acquisition. We actively seek diverse talents for key board and senior roles.
As the CEO, Director, and Founding Member of BluMaiden Biosciences, Damien Keogh, Ph.D., leads a platform company that leverage ...
As the CEO, Director, and Founding Member of BluMaiden Biosciences, Damien Keogh, Ph.D., leads a platform company that leverages artificial intelligence to identify biomarkers and small molecule therapeutics from the human microbiome. Dr. Keogh has been serving as Chief Executive Officer and Board of Directors Member since August 2020. Prior to co-founding the Company, he was actively engaged in the Biotechnology sector with roles in venture capital as Entrepreneur-in-residence, spin-out and venture created biotechnology companies. He has also earned alumni status at Johnson & Johnson Innovation JLABS. Dr. Keogh continues to support and engage with both start-up companies and entrepreneurs in their strategic positioning and development.
During his academic career Dr. Keogh worked closely with Pharma leaders, clinician scientists, and academic research scientists to develop new methods and insights to metabolite biology, (poly)microbial-host interactions, and microbial biofilm dynamics. His early research work was sponsored by the Pharmaceutical company Bristol Myers Squibbs Ltd. with the aim of developing molecular tools to enhance drug purification with novel glycoselective bioaffinity tools. Dr. Keogh has many years of experience working with multidisciplinary scientific teams to develop insights and applications with state-of-the-art technologies.
Mr. Tillmann is a seasoned CEO, board member and entrepreneur with 30 years of experience in the pharmaceutical and diagnostics ...
Mr. Tillmann is a seasoned CEO, board member and entrepreneur with 30 years of experience in the pharmaceutical and diagnostics industry. Mr. Tillmann has a stellar 30-year track-record in the pharmaceutical and diagnostics industry. Having served Roche Diagnostics as its Asia Pacific and North America CEO with a seat in the Roche Global Executive Board, Mr. Tillmann has been running his own bio-tech incubator Amatar Group since 2010. In this role, he also founded Vela Diagnostics Ltd, which was acquired by the Luye Lifescience Group in 2020. Mr. Tillmann sits in multiple supervisory & advisory boards. Additionally, he supports companies in their strategic positioning and M&A activities, where he advised in his latest project AmpTec GmbH, which was acquired by Merck KGaA, Germany.
Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compound ...
Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is expert in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.
Between 1990 and 2009, Terry served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department. From 2010 – 2016 he was the CEO and CSO of CoMentis, Inc, a venture-backed biotech focusing on treating cognitive disorders. He is a founder of Kelly Pharma Research Consulting, LLC and has served as a director of Cardax, Inc. since June 2014. Terry is currently the President and CEO of Perception Neuroscience, a clinical stage biotech company developing small molecule therapeutics for mental health disorders.
Terry holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute and a Ph.D. degree in Chemistry at the University of Texas at Austin. He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University. Dr. Kelly is the co-author of over 25 scientific publications and served on the College of Natural Sciences Advisory Council for the University of Texas.
Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct in ...
Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct investments in early-stage opportunities. Robert is also the CEO of Caber Partners Pte Ltd, an Alternative Asset Manager licensed by the Monetary Authority of Singapore (MAS) as Fund Manager and Exempt Financial Advisor. In June 2021, Caber launched the Angsana Natural Rubber Opportunities Fund I (“ANRO”), a macro hedge fund that positions in rubber futures and derivatives. Prior to launching Angsana, Robert co-founded SGX-listed Halcyon Agri Corporation Limited and served as its CEO from January 2013 to June 2020. During his tenure, Halcyon Agri executed a buy-and-build roll-up strategy to create the world’s largest rubber franchise. In 2016, Halcyon Agri acquired the natural rubber business of Chinese state-owned Sinochem International Limited in a landmark transaction that valued the enlarged group at USD800m. At Halcyon Agri, Robert also initiated the launch of HeveaConnect, the world’s first digital marketplace for sustainable natural rubber, in partnership with Itochu Corporation and DBS Bank Limited and, most recently, SGX. Robert has a keen interest in geopolitics and served on Singapore’s Economic Strategies Committee (ESC) in 2010. Presently, Robert is a member of the National University of Singapore Health International Council (NIC).
With over 30 years of experience in the IT industry, Mr. Gorriz is currently an Independent Non-Executive Director of Mercedes- ...
With over 30 years of experience in the IT industry, Mr. Gorriz is currently an Independent Non-Executive Director of Mercedes-Benz Automobile Finance Co., Ltd. in China, Non-Executive Director of mox Bank (a virtual bank in Hong Kong), Non-Executive Director of Swiss IT Security AG (an IT security service group based in Switzerland) and Kyberlife (an e-commerce marketplace start-up for life sciences, pharmaceutical, and healthcare industries headquartered in Singapore). Mr. Gorriz is also currently a Board Advisor to Axis Bank Limited in India and member of the Advisory Board of zscaler (NASDAQ: ZS), a cloud security company headquartered in San Jose, California. He is a Senior Executive Education Fellow at the National University of Singapore’s School of Computing teaching about Cloud Migration and Adoption and Digital Transformation.
From 2015 to 2021, Mr. Gorriz has served as the Chief Information Officer for Standard Chartered Group from 2015 to 2021. During his tenure, he was responsible for the systems development and technology infrastructure which underpin Standard Chartered Group’s client services. He was also responsible for defining and implementing Standard Chartered Bank’s digital and innovation agenda. Prior to joining Standard Chartered, Mr. Gorriz was Vice President and Chief Information Officer at Daimler AG where he was globally responsible for strategy, planning and development of the Daimler Group’s IT systems, as well as the operation of its technical infrastructure. During his 29 years at Daimler, Mr. Gorriz progressed through specialist research and design roles in aerospace to general management roles.
Mr. Gorriz is an industry acclaimed technology leader and has won numerous awards – including the Global CIO award of the Indian NASSCOM and is one of only three CIOs in Germany nominated to a list of the 40 most important people in IT in the last 40 years. Mr. Gorriz is a physicist and engineer by background and obtained a PhD in Engineering.
Kevin’s expertise reflects a diverse tapestry of industries, firmly establishing him as a seasoned professional. His educ ...
Kevin’s expertise reflects a diverse tapestry of industries, firmly establishing him as a seasoned professional. His educational journey commenced with a BSc in Computer Science and Management from the esteemed University of Liverpool, igniting his career in Ecommerce consulting and IT solutions development.
A trailblazing entrepreneur, Kevin not only co-founded but also spearheaded thriving
ventures encompassing advertising, web solutions, agriculture, and property development.
Notably, he masterminded successful exits from the advertising and web solutions arena.
From 2015 onwards, Kevin embraced a more proactive stance, channeling his resources into
start-ups, with a pronounced emphasis on medical technology and education. This strategic
move positioned him as a hands-on advisor, nurturing direct engagement with these
enterprises. His impact reverberated, culminating in his directorial role at Perspectum Ltd., a
position impeccably executed from 2020 to 2023. Even today, Kevin’s influential presence
endures as an observer and active participant within the Asia office.
Oleg Moskvin, PhD is a computational biologist who brings together experiences and mindsets from network-centric *omics data an ...
Oleg Moskvin, PhD is a computational biologist who brings together experiences and mindsets from network-centric *omics data analysis in both prokaryotic and eukaryotic systems, genome analysis, and classical biochemistry. His academic career involved the discovery of novel functionality in bacterial genomes, and extensive *omics studies related to areas ranging from biofuel research and bacteria-environment interactions to stem cell differentiation, supplemented with the development of related computational approaches. The number of publications that cite Dr. Moskvin’s work exceeds 2,600.
In 2018-2022, in the role of Group Lead of Wilmar Intl R&D, he brought his expertise to setting up, conducting, data analysis and follow-up studies of the gut microbiome part of the dietary intervention clinical trials. That included function-centric microbiome analysis, development of a cutting-edge custom protocol for long-read metatranscriptomics, as well as whole-genome metabolic modeling of key bacterial species. Dr. Moskvin’s multifaceted vision of the microbiome area aligns well with BluMaiden goals.
Lakshmanan is a technologist with extensive experience (17+ years) in the designing (solution architecture, product management) ...
Lakshmanan is a technologist with extensive experience (17+ years) in the designing (solution architecture, product management) and delivering (systems integration, management of data teams) complex software solutions leading to capability uplifts, costs reductions and business process optimizations for Fortune 500 Companies across Banking, Financial services, Retail, Software vendors, digital native, healthcare, and Utilities.
In most recent role, as senior consultant at Amazon Web Services (AWS) his remit was across ASEAN to deliver high-touch assistance and guidance to enterprise customers and software vendors as they shift to a cloud-based operating model and incorporate AWS services into their overall architecture. Work together with customer teams and AWS partners to provide deep expertise in the architecture, design, development, and implementation of cloud computing initiatives that result in real business outcomes. In addition to delivering customized services, he has built repeatable solutions that accelerate AWS adoption, and provides meaningful customer insights that inform our service roadmaps.
Rohan Williams is a computational biologist, specialising in bioinformatics and systems biology of microbiomes and microbial ec ...
Rohan Williams is a computational biologist, specialising in bioinformatics and systems biology of microbiomes and microbial ecology. Following undergraduate studies in Physics he obtained a PhD in Medicine at the University of New South Wales (Sydney, Australia) in the field of human gastrointestinal physiology, and undertook postdoctoral work in computational genetics and genomics, before obtaining an academic appointment at the John Curtin School of Medical Research, Australian National University, Canberra in 2007. He relocated to Singapore in 2011 to commence as a principal investigator of the Singapore Centre for Environmental Life Sciences Engineering (SCELSE), a Research Centre of Excellence co-hosted by the National University of Singapore and Nanyang Technological University, where he is the Head of the SCELSE Integrative Analysis Unit. At SCELSE he and his research group develop new methods for analysing the composition and function of microbiomes, with particular focus on the use of long read sequencing technology and multi-omics. Williams holds diverse research perspectives from this experience working in basic, clinical and environmental settings, including collaborations with two multinational companies and government agencies. He has published around 80 research papers, review articles and book chapters.
Distinguished Laureate Professor Nicholas Talley AC is a Scientific Advisory Board member at BluMaiden Biosciences. Currently h ...
Distinguished Laureate Professor Nicholas Talley AC is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is based at the University of Newcastle, Australia and held former appointments as Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida, a Professor of Medicine and Professor of Epidemiology at Mayo Clinic and Foundation Professor of Medicine at the University of Sydney, Nepean Hospital.
Professor Talley is considered one of the world’s leading authorities in diseases of the upper and lower gastrointestinal tract. Among other advances, his research has documented genetic determinants of irritable bowel syndrome (IBS), and the role of the immune system and gut microbiota in functional gastrointestinal disease. At BluMaiden Biosciences, he is guiding the scientific team as they develop pioneering solutions to human microbiome associated diseases.
Professor Damian O’Connell is Chief Executive Officer the Experimental Drug Development Centre at A*Star – the Agen ...
Professor Damian O’Connell is Chief Executive Officer the Experimental Drug Development Centre at A*Star – the Agency for Science, Technology and Research based in Singapore. The Experimental Drug Development Centre is a national platform for drug and biomarker discovery as well as early clinical development.
Most recently Damian was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Prof O’Connell previously held senior positions within Pfizer Research & Development, Parke Davis, Elan Pharmaceuticals and Neurex. Prof O’Connell has both MD & PhD degrees from the National University of Ireland, has been a Medical Faculty member of the University of Virginia Health Sciences Center as well as a member of the Clinical Pharmacology & Therapeutics Department at the University College Cork, Ireland where he was a Professor of Clinical Research. He started his career in the Industry in 1998.
Prof O’Connell is an Adjunct Professor at University College Cork, Ireland; Member Expert Advisory Panel, Singapore Translational Cancer Consortium; Member Advisory Board Investigational Medicine Unit SingHealth, Singapore; Board Member INFANT Research Centre, Cork Ireland; Member Scientific Advisory Board, BluMaiden Biosciences, Singapore; Member of the Faculty of Pharmaceutical Medicine; Fellow of The Royal Society of Medicine; Fellow of The Royal Academy of Medicine (Ireland); Member of the British Pharmacological Society; Member of the Drug Safety Executive Council (DSEC); Member American Society for Clinical Pharmacology and Therapeutics; Member American College of Clinical Pharmacology.
Professor Kim Lewis – Professor Kim Lewis is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is ...
Professor Kim Lewis – Professor Kim Lewis is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is a University Distinguished Professor and the Director of Antimicrobial Discovery Center at Northeastern University in Boston, Massachusetts. Formally he held faculty appointments at Massachusetts Institute of Technology, University of Maryland and Tufts University. A distinguished molecular microbiologist whose research career has focused on the mechanisms of antimicrobial resistance, Lewis is a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology.
Lewis’ research has resolved key problems underpinning the mechanisms by which bacteria can resist the action of antibiotics, discovered new classes of antibiotics and demonstrated the potential of finding antibiotic compounds in microbiomes. Lewis has a long-standing engagement with the biotech industry and pharma. At BluMaiden Biosciences, he is guiding the scientific team on approaches for discovering new therapeutic compounds from human microbiomes.
Professor Stephen Simpson, FRS is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is the Director of ...
Professor Stephen Simpson, FRS is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is the Director of the Charles Perkin Centre at the University of Sydney, a Professor in the School of Life and Environmental Sciences at the University of Sydney, and Executive Director of Obesity Australia. Prior to his current appointments, Simpson was at the University of Oxford for over 20 years. In 2013 he was elected a Fellow of the Royal Society of London as “one of the world’s foremost entomologists and nutritional biologists”.
Simpson is a highly innovative thinker in nutritional science, having developed new measurement and modelling frameworks for studying nutritional intake behaviours in a range of organisms, including humans. This approach, termed nutritional ecology, draws on ecology and evolutionary theory to provide a new foundation for thinking about human nutrition. At BluMaiden Biosciences, he is guiding the scientific team in their attempts to build a platform for microbiome-enabled personalized nutrition.
● Computational Biology
● Computational Chemistry
● Disease Biology
● Clinical Science
● Information Technology
+ We push boundaries to address unmet needs in novel ways
+ Challenge convention to reshape the norm
+ Innovative integrated platform technology and analytics streamlines the path to drug discovery
+ Visionaries who prioritize end results
+ We integrate data capture, analysis, and discovery for a seamless drug discovery process
+ Forge partnerships and engage in impactful co-creation with consumers and pharmaceutical companies
+ Chase elevated intellectual and scientific precision
+ Embrace hurdles and trials as opportunities to enhance and pioneer
+ We invest in people, the bedrock of a lasting enterprise
+ We take responsibility for our actions
+ Operate with conviction, compassion and empathy
+ Adhere to elevated ethical standards in our research and processes
+ Devoted to advancing science for the betterment of all
At the core of our beliefs lies a firm commitment to Compliance & Ethics, vital for fostering trust among patients, business partners, shareholders, and communities. Our business operations prioritize transparency, aligning unfailingly with our vision and values articulated in the Code of Conduct. Accountability is paramount as we continually strive to meet the standards we set ourselves.
If you have a general question for us or want to explore a partnership opportunity, then please reach out to us here…[ Contact Us + ]